FDA Determines Regulatory Review Period for CARTIVA Patent Extension

Summary

The U.S. Food and Drug Administration (FDA) has officially confirmed the regulatory review period for CARTIVA, a medical device patent extension application submitted to the U.S. Patent and Trademark Office (USPTO), as required by law.